Literature DB >> 11744342

Particulate contamination in parenteral nutrition solutions: still a cause for concern?

P A Ball1, K Bethune, J Fox, R Ledger, M Barnett.   

Abstract

OBJECTIVES: In consideration of a US Federal Drug Administration recommendation that all parenteral nutrition admixtures should be administered through an in-line filtration device, this observational study examined the number, size distribution, and sources of particulate contamination in parenteral nutrition admixture infusion systems.
METHODS: Samples were drawn from the terminal connection of the infusion tubing before connection to the patient. The particles were sized and counted by optical microscopy and further investigated by electron microscopy and energy disperse spectroscopy.
RESULTS: Large numbers of particles were found, and information gained about their possible origin.
CONCLUSIONS: This study provides further support for the adoption of this Federal Drug Administration recommendation.

Entities:  

Mesh:

Year:  2001        PMID: 11744342     DOI: 10.1016/s0899-9007(01)00708-0

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  3 in total

1.  Micro-flow imaging: flow microscopy applied to sub-visible particulate analysis in protein formulations.

Authors:  Deepak K Sharma; Dave King; Peter Oma; Clark Merchant
Journal:  AAPS J       Date:  2010-06-02       Impact factor: 4.009

2.  Effect of the intravenous lipid emulsions on the availability of calcium when using organic phosphate in TPN admixtures.

Authors:  Sonia Chaieb D; Jean Claude Chaumeil; Sami Jebnoun; Naima Khrouf; Abderrazek Hedhili; Souad Sfar
Journal:  Pharm Res       Date:  2008-08-22       Impact factor: 4.200

3.  In-line filtration reduced phlebitis associated with peripheral venous cannulation: Focus on cost-effectiveness and patients' perspectives.

Authors:  Gianluca Villa; Rosa Giua; Timothy Amass; Lorenzo Tofani; Cosimo Chelazzi; Fulvio Pinelli; A Raffaele De Gaudio; Stefano Romagnoli
Journal:  J Vasc Access       Date:  2019-07-26       Impact factor: 2.326

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.